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ABSTRACT
Background. Different strategies can be used to counteract coagulation of extracorporeal systems. Systemic anticoagulation
is most widely used in routine clinical practice, but can be contraindicated in specific settings. The Solacea
TM
dialyser,
containing the asymmetric triacetate membrane, claims improved biocompatibility, which should result in decreased
tendency for coagulation. We quantified the performance of the Solacea
TM
versus the FX800CORDIAX dialyser regarding
resistance to fibre blocking as assessed by micro-computed tomography (CT).
Methods. This cross-over study with four arms randomized consecutively 10 maintenance haemodialysis patients to a 4-h
post-dilution haemodiafiltration session at midweek, using either Solacea
TM
19 H or FX800CORDIAX, with either regular or
half dose of anticoagulation (EC2017/1459-NCT03820401). Dialyser fibre blocking was visualized in the dialyser outlet
potting using a 3D CT scanning technique on micrometre resolution. Extraction ratios of middle molecules [myoglobin,
lambda and kappa free light chains (FLCs)] were determined.
Results. The relative number of open fibres post-dialysis was lower in FX800CORDIAX versus Solacea
TM
dialyser, and this was
irrespective of the anticoagulation dose used or the threshold for counting open fibres. Extraction ratios of FLCs were not
different at regular anticoagulation between Solacea
TM
and FX800CORDIAX (21%6 4% for kappa and 32%68% for lambda
with Solacea
TM
versus 23%67% and 38%6 6% for FX800CORDIAX), but were superior with the Solacea
TM
(34%612% versus
22%6 8% with FX800CORDIAX; P¼0.02) for myoglobin in case of halving anticoagulation dose. No clinically relevant
albumin loss was detected.
Conclusions. The Solacea
TM
dialyser seems to be promising for use in conditions where systemic anticoagulation is
contraindicated, as even under conditions of low systemic anticoagulation, virtually no signs of fibre blocking could be
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observed using the sensitive micro-CT scanning technique. This finding is in line with its presumed good performance in
terms of biocompatibility.
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INTRODUCTION
The retention of uraemic toxins in patients with end-stage kid-
ney disease (ESKD) has been associated with inflammation and
increased cardiovascular risk. The removal of middle molecules,
such as b2-microglobulin (b2M), and of protein-bound toxins,
such as indoxylsulphate, is rather poor with conventional low-
flux dialysis, whereas these contribute probably most to urae-
mic toxicity [1, 2]. In an attempt to reduce inflammation and
thus cardiovascular toxicity, the use of haemodiafiltration
(HDF) or of more open membranes has been promoted to en-
hance clearance of middle molecular weight substances during
dialysis [3].
Membranes used in online HDF treatment must have high
permeability while still keeping albumin (Alb) leakage to a mini-
mum. Polysulfone and polyethersulfone membranes have gen-
erally been used to satisfy these requirements. However, these
membranes are sometimes associated with hypersensitivity
reactions, attributed to the use of additives such as polyvinyl-
pyrrolidone to enhance hydrophilic properties [4]. As the asym-
metric triacetate (ATA
TM
) membrane is manufactured without
hydrophilization agents, it was found to have a lower risk of hy-
persensitivity, and less decrease in platelets. It has a dense skin
layer on the internal surface at blood side, and an external sup-
port layer with large pores, maintaining high permeability and
filtration performance [4].
Coagulation within the dialyser membrane fibres is an obvi-
ous biological sign of bio-incompatibility [5]. To avoid clotting
during extracorporeal treatment, an anticoagulant is added to
the circuit, resulting in an increased risk for bleeding complica-
tions. In clinical practice, it regularly happens that patients
needing extracorporeal treatment have a relative contraindica-
tion for systemic anticoagulation, for example, because of active
bleeding (gastrointestinal conditions) or with increased bleeding
risk (peri-operative period). Disposing of membranes with low
procoagulant properties, so that the need for systemic anticoa-
gulation can be minimized, can thus be a true clinical advantage.
In addition, there is evidence that a substantial number of
fibres can become blocked before this is reflected in routinely
observed parameters, or in termination of the dialysis session
[6]. Little is known about the impact of such subclinical clotting
on dialyser performance in terms of solute clearance.
Membrane clogging due to deposition of proteins and red
blood cells on the dialysis membrane may influence both the
diffusive and convective transport characteristics of the dialyser
membrane before leading to complete dialyser clotting [7–9].
Recently, a method was described to objectively count the num-
ber of blocked fibres inside a dialyser using a micro-computed
tomography (CT) scanning technique [6]. This method can thus
also be used to assess the resistance of the dialyser to clotting
and to evaluate the impact of subclinical fibre blocking on sol-
ute removal and thus the performance of a dialyser during a di-
alysis session.
The aim of this randomized cross-over study was to objectively
quantify the performance of the Solacea
TM
dialyser containing the
ATA
TM
membrane, and compare it for different performance out-
comes with those of the FX800CORDIAX dialyser containing a
polysulfone membrane. To more intensely activate the coagula-
tion cascade, dialysis was performed once with regular and once
with only half of the regular anticoagulation dose. We used resis-
tance to fibre blocking as assessed by micro-CT as primary out-
come, and dialyser clearances of small water soluble solutes and
middle molecules, and Alb loss, as secondary outcome.
MATERIALS ANDMETHODS
Patients
Power analysis was based on data from a previously performed
cross-over study in patients dialysed with two different types of
dialyser [10]. Using the relative number of patent fibres as pri-
mary outcome, power was 69% (a¼ 0.05) including only six
patients. Therefore, this single-centre randomized cross-over
study with four treatment regimens included 10 consecutive
stable chronic haemodialysis (HD) patients [aged 65.96 16.3
years, 15.2 (9.6–25.9) months on dialysis, and all male]. Patients
were eligible when they had experienced stable dialysis ses-
sions during the last 4 weeks, and had no known coagulation
disorder, active inflammation or malignancy.
Since test sessions were scheduled at midweek with a wash-
out period of 1 week, test sessions can be considered as inde-
pendent and sequence order impact can be accepted to be
absent. Furthermore, patients are serving as their own control
such that simple randomization is allowed. At inclusion,
patients were sequentially numbered (by the including nephrol-
ogist) for further simple randomization (www.randomization.
com) (by the investigator) (Figure 1).
FIGURE 1: Patient flow.
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Double-needle vascular access was achieved through a na-
tive arteriovenous fistula (n¼ 7) or a well-functioning double-
lumen tunnelled central venous catheter, either HemostarVR
14.5 F (n¼ 2) (Bard, Salt Lake City, UT, USA) or PalindromeTM
14.5 F (n¼ 1) (Medtronic, Minneapolis, MN, USA). Regular treat-
ment of these patients was post-dilution HDF with high-flux
dialysers FX800CORDIAX (n¼ 9) (Fresenius Medical Care, Bad
Homburg, Germany) or Polyflux 170 H (n¼ 1) (Baxter, Deerfield,
IL, USA).
The protocol was approved by the institutional research
committee (Ethical Committee—Ghent University Hospital, EC
2017/1459-B670201734230—March 2018), and registered as part
of a larger study in www.ClinicalTrials.gov (NCT03820401).
Written informed consent was obtained from all included
patients.
Dialysis and anticoagulation
In the study protocol, each patient was dialysed for 240 min in
four different regimens, randomly using two different dialysers
and two different anticoagulation schemes. All study sessions
were performed at midweek in the dialysis unit of the Ghent
University Hospital (Belgium) in the period 2–29 March 2018.
The two dialysers investigated were the ATA
TM
Solacea
TM
19 H
(Nipro, Osaka, Japan) and the Helixone polysulfone
FX800CORDIAX (Fresenius Medical Care, Bad Homburg,
Germany). For optimal comparison, surface areas of both dialy-
sers were selected to be approximately identical (Table 1).
Patients received their regular brand of low-molecular-
weight heparin (Tinzaparin, Leo Pharma, Belgium) anticoagula-
tion at the beginning of the dialysis session, and this randomly
is either at their regular dose (full dose 1/1) or at only 50% of
their regular dose (half dose 1/2).
All test sessions were performed on a 5008 dialysis machine
(Fresenius Medical Care, Bad Homburg, Germany) with blood
flow at 300 mL/min and dialysate flow at 500 mL/min in post-di-
lution HDF mode. Substitution flow was set 25% of blood flow
(i.e. 75 mL/min). Ultrafiltration rates were set according to the
patient’s interdialytic weight gain and clinical status.
In this way, each patient served as his own control and was
randomized over four test sessions at midweek (Figure 2). Each
experimental session was preceded with two wash-in sessions
with the same type of dialyser to be used in the experimental
dialysis, but always with full regular anticoagulant dose.
Blood sampling, laboratory and calculations
During the four experimental midweek sessions, blood was
sampled from the arterial and venous blood lines, and spent di-
alysate was sampled from the outlet line, all at 60 min after the
dialysis start. Blood samples were immediately centrifuged and
serum and dialysate were stored at 80C until batch analysis
in the routine laboratory of the Ghent University Hospital.
Concentrations of the small water-soluble solute urea were
determined by routine analysis, while those of the middle mole-
cules kappa and lambda free light chains (FLCs), and myoglobin
were determined by nephelometry. Colorimetric bromocresol
green assay was used to determine Alb concentrations.
Extraction ratios (ER) were calculated from the arterial and
venous plasma concentrations (Carterial and Cvenous), accounting
for haemoconcentration (based on Alb levels) for the middle
molecules:
ER %ð Þ ¼ Carterial  Cvenous  ðAlbarterial=AlbvenousÞ
Carterial
 100 (1)
Alb loss during the dialysis session was quantified from
adsorption and transmembrane loss in the dialysate.
Adsorption of Alb and the middle molecules was calculated
from the mass balance in the dialyser, accounting for haemo-
concentration (using ultrafiltration rates):
Adsorption ðg=minÞ ¼ ½Carterial  QB  ½Cvenous  ðQB  QUFÞ
 ½Cdialysate  ðQD þ QUFÞ (2)
where QB is bloodflow, QD is dialysate flow and QUF is
ultrafiltration.
Micro-CT scanning and coagulation quantification
To quantify the primary outcome measure, i.e. incidence of fi-
bre blocking, of the dialysers after 4 h HDF, dialysers were
scanned with a reference non-invasive micro-CT scanning tech-
nique [6]. In brief, at the end of the dialysis session, a standard
rinsing procedure of the haemodialyser was performed using
exactly 300 mL of rinsing solution. Next, the haemodialyser was
dried for 24 h using continuous positive pressure ventilation, si-
multaneously in blood and dialysate compartment. Dialyser fi-
bre blocking was visualized in the dialyser outlet potting using a
3D CT scanning technique on micrometre resolution, as previ-
ously described [6].
Table 1. Properties of the different dialysers
Membrane Area (m2) KUF (mL/h/mmHg) Dfibre (mm) D (mm) Sterilization technique Sieving coefficient
Solacea
TM
19H ATA
TM
1.9 72 200 25 Gamma 0.85
FX800CORDIAX PS 1.8 63 210 35 INLINE steam 0.90
KUF, ultrafiltration coefficient; Dfibre, fibre diameter; D, membrane thickness.
FIGURE 2: Test protocol.
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For this study, three different thresholds were used to
define the surface area of an open fibre: i.e. 50, 70 and 90% of
the cross-section of a non-used fibre. Comparing the number of
non-blocked fibres in the tested dialyser with the total number
of fibres as measured in three non-used dialyser samples pro-
vided an objective estimate of the percentage of fibre blocking.
Statistical analysis
Statistical analyses were performed using SPSS version 24 (SPSS
Inc, Chicago, IL, USA). Continuous variables were summarized
as mean6SD, and median value with interquartile range. To
compare different related variables, ANOVA tests were per-
formed with Tukey’s HSD post hoc test (normal distributions) or
Friedman tests with Wilcoxon post hoc test (no normal distribu-
tions). A general linear model was used to assess eventual inter-
action between membrane and anticoagulation dose effects.
RESULTS
Relevant demographic and clinical data of the patient popula-
tion at baseline are summarized in Table 2. There were no pa-
tient dropouts during the experimental period, all flow settings
were maintained according to the protocol, and no adverse
events were recorded. Table 3 shows the dialysis durations and
the ultrafiltration rates in the four test sessions.
The reconstructed images of the cross-sections halfway the
outlet potting are presented in Figure 3 for the 10 patients and
for the four experimental dialysis sessions. The lumina of open
fibres are visualized as black dots.
The number of open fibres in the three non-used Solacea
TM
and FX800CORDIAX dialyser samples was 12 08764 and
13 0516 1, respectively, indicating high consistency in the num-
ber of fibres in non-used dialysers for both dialyser types.
For the four test sessions, the number of dialysers with
>50% open fibres are presented in Figure 4 for the different
thresholds of considering fibres as being open (i.e. 50, 70 and
90% open fibre area). The numbers of open fibres relative to the
number in non-used dialysers are given in Table 4. For a fixed
anticoagulation protocol (either 1/1 or 1/2), irrespective of the
considered threshold for counting open fibres, the relative num-
ber of patent fibres was lower in FX800CORDIAX versus
Solacea
TM
dialyser. Accounting for 50 or 70% open area, halving
anticoagulation resulted in relatively less open fibres as com-
pared with full anticoagulation in the FX800CORDIAX, while no
differences were seen in the Solacea
TM
dialyser.
In the general linear model, membrane type [Solacea
TM
ver-
sus FX800CORDIAX, b¼0.205, 95% confidence interval (CI)
0.39 to 0.019; P¼ 0.03] but not anticoagulation dose (full ver-
sus half, b¼ 0.101, 95% CI 0.085 to –0.286; P¼ 0.28) influenced
the number of open fibres at 50%. There was no interaction be-
tween membrane type and anticoagulation dose on the effect
on the number of open fibres.
Differences in clotting in both dialysers are also visualized in
Figure 5. We observe that, overall, Solacea
TM
shows more open
fibres versus FX800CORDIAX. Also, there is clearly a more sub-
stantial drop in number of fibres considered as open when the
criterion shifts from 70% to 90% open fibre area. This indicates
that the fibres of Solacea
TM
are resistant to even small degrees of
fibre blocking during dialysis.
Concentrations of urea, Alb, myoglobin, and kappa and
lambda FLCs as measured in blood sampled from the arterial
and venous dialysis blood line, and from the spent dialysate
line, are shown in Table 5. Alb concentrations in the spent dialy-
sate were below the limit of detection (LOD), and no differences
were found between the arterial and venous mass flow of Alb,
suggesting the absence of Alb adsorption. While negligible
adsorption onto the dialyser membrane was found for myoglo-
bin, a substantial but comparable adsorption was found for
kappa and lambda FLCs for both membranes (Table 6).
Table 6 also shows the extraction ratios of urea and the
middle molecules for the four dialysis scenarios at 60 min after
dialysis start. For the Solacea
TM
with standard anticoagulation,
extraction ratios were 2164% (kappa FLC), 3268% (lambda
FLC) and 32610% (myoglobin), which were not different from
those with the FX800CORDIAX. With half anticoagulation,
however, extraction ratios for myoglobin were superior with
the Solacea
TM
(346 12% versus 2268% with FX800CORDIAX;
P¼ 0.019). In general, irrespective of the anticoagulation dose,
myoglobin extraction ratios were higher with Solacea
TM
versus
Table 3. Characteristics of the dialysis sessions in the different experimental settings
Solacea_1/1 Solacea_1/2 FX800CORDIAX_1/1 FX800CORDIAX_1/2
Dialysis duration, min 24162 24064 24162 2416 3
VUF, mL 1650 (750–2175) 1695 (1500–2375) 1800 (1200–2325) 1700 (1350–2375)
Total convective volume, L 17.3 (17.3–17.5) 17.4 (17.4–17.7) 17.4 (17.4–17.6) 17.2 (17.1–17.6)
Values are expressed as mean6SD or median (25–75%); VUF, ultrafiltration volume over the session.
Table 2. Demographic and clinical data of the patient population at
baseline
Gender (male/female) 10/0
Age, years 65.96 16.3
BMI, kg/m2 27.76 7.0
Dialysis vintage,
months
15.2 (9.6–25.9)
Renal disease Nephroangiosclerosis (n¼ 3); diabetic
nephropathy (n¼ 2); IgA nephropathy
(n¼ 1); focal segmental glomeruloscle-
rosis (n¼ 1); retroperitoneal fibrosis
(n¼ 1); renal cell carcinoma (n¼ 1);
Alport (n¼ 1)
Regular anticoagulation
dose
Tinzaparin 3500 (n¼ 3); Tinzaparin 4500
(n¼ 7)
Anticoagulation/body
weight (U/kg)
49 (47–61)
Platelet inhibitors Acetylsalicylic acid 80 mg (n¼ 5)
Hb (g/dL) 10.76 1.2
Platelets count (103/mL) 217646
aPTT (s) 38.76 5.9
INR () 1.06 0.1
CRP (mg/L) 9.3 (6.4–12.0)
Values are expressed as mean6SD or median (interquartile range) unless other-
wise specified. BMI, body mass index; IgA, immunoglobulin A; Hb, haemoglobin;
aPTT, activated partial thromboplastin time; INR, international normalized ra-
tio; CRP, C-reactive protein.
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FX800CORDIAX, while in both dialyser types no impact of anti-
coagulation dose on extraction ratio could be observed 60 min
after dialysis start.
DISCUSSION
The present randomized cross-over study investigated the per-
formance with respect to fibre blocking, middle molecule
removal and Alb loss of the Solacea
TM
and FX800CORDIAX dialy-
sers, and using either 100% or 50% of the regular anticoagulation
dose.
Our main finding is that Solacea
TM
outperforms
FX800CORDIAX in avoiding clotting as expressed by the relative
number of open fibres at the end of the dialysis session, and
this is even more so when the coagulation cascade is challenged
by using only half the regular dose of anticoagulation. We
FIGURE 3: Cross-sections halfway the potting in 10 patients and four tested settings. The grey scale range is from 0 to 0.5/cm and the scale bar denotes 10 mm.
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observed a decrease in extraction ratio of middle molecules rep-
resented by myoglobin due to fibre blocking during dialysis with
the FX800CORDIAX, a decrease in efficiency that can go unno-
ticed using current monitoring techniques. Both membranes
resulted in comparable extraction ratios of Kappa and Lambda
FLCs. There is practically no Alb loss when using the Solacea
TM
or the FX800CORDIAX dialyser.
Coagulation within the extracorporeal circuit can result in a
precocious termination of the dialysis treatment, or worse, loss
of extracorporeal circuit and the blood contained in it. To avoid
this, many dialysis units have a policy of liberal use of anticoag-
ulant agents, which might, however, result in more bleeding
episodes [11]. In conditions where extracorporeal treatment is
necessary but systemic anticoagulation should be avoided, e.g.
with active bleeding or increased bleeding risk, it is important
to select a dialyser that activates the coagulation cascade as
minimally as possible. Our data indicate that in these condi-
tions, using a Solacea
TM
dialyser allows safe reduction of the reg-
ular dose of systemic anticoagulant.
Other options in such a setting are local anticoagulation us-
ing citrate or calcium zero dialysate [12–15], or using heparin-
coated membranes. Use of local anticoagulation with citrate is
considered safe, but is logistically cumbersome in a chronic set-
ting [12]. Use of heparin-coated membranes has been estab-
lished in clinical practice, but the evidence to underpin this
strategy is small [16, 17]. Of note, in our study, no dialysis ses-
sions had to be terminated prematurely, but using a more sensi-
tive gold standard technique to evaluate fibre blocking, we
noted a substantial reduction in percentage of open fibres using
FX800CORDIAX, whereas this was absent with Solacea
TM
, even
when applying a half dose of anticoagulation. In small, single-
centre studies [18, 19] regional anticoagulation by either a
heparin-coated membrane, regional citrate or regional citrate
and calcium 0 has been evaluated, with varying success.
Overall, the use of a Solacea
TM
membrane seems thus to be a
promising, easily manageable, efficacious and safe strategy in
conditions where no systemic anticoagulation can be used.
It is generally accepted that activation of the coagulation
cascade is influenced by bio-incompatibility [20]. Our observa-
tion that, during a regular dialysis session, only a limited degree
of fibre blocking occurred even with substantially reduced sys-
temic anticoagulation seems to suggest good biocompatibility
of the Solacea
TM
ATA
TM
membrane. Using citrate as local antico-
agulant also inhibits clotting, but does not restore bio-
incompatibility issues related to the membrane, and does not
block the activation of white blood cells or complement [21, 22].
On a theoretical basis, differences in coagulation and fibre
clotting could also be induced by differences in rheological prop-
erties of the blood because of large differences in protein content.
However, within this population, no differences in baseline Alb
concentrations were present, and there was also no indication of
paraproteinemias, making this less likely. In addition, each pa-
tient was his own control, so the conclusions with regard to the
behaviour of the different membranes would still hold.
Compared with events associated with actual clinical clot-
ting of the extracorporeal circuit, less is known about the im-
pact on dialyser performance and clearance of subclinical fibre
blocking, i.e. without the need to terminate the dialysis session
FIGURE 4: Number of dialysers with >50% of fibres considered as open according
to the criteria of 50, 70 or 90% of single fibre area being free of clotting.
Table 4. Relative number of open fibres in the four tested dialysers versus non-used dialysers for the thresholds of 50, 70 and 90% open fibre
area
Solacea_1/1, median
(25–75%);
(min–max)
Solacea_1/2, median
(25–75%);
(min–max)
FX800CORDIAX_1/1,
median (25–75%);
(min–max)
FX800CORDIAX_1/2,
median (25–75%);
(min–max)
Friedman,
P-value
50% open area 1.00 (1.00–1.00);
(1.00–1.00)
1.00 (1.00–1.00);
(0.99–1.00)†
0.97 (0.97–0.99);
(0.16–1.00)†,‡
0.91 (0.57–0.97);
(0.29–0.99)†,‡,*
<0.001
70% open area 1.00 (1.00–1.00);
(1.00–1.00)
1.00 (0.99–1.00);
(0.98–1.00)
0.97 (0.97–0.99);
(0.15–0.99)†,‡
0.91 (0.56–0.97);
(0.28–0.99)†,‡,*
<0.001
90% open area 0.95 (0.94–0.99);
(0.88–1.00)
0.97 (0.95–0.98);
(0.88–1.00)
0.89 (0.85–0.91);
(0.10–0.93)†,‡
0.84 (0.40–0.89);
(0.20–0.92)†,‡
<0.001
†
P<0.05 versus Solacea_1/1; ‡P< 0.05 versus Solacea_1/2; *P<0.05 versus FX800CORDIAX_1/1.
FIGURE 5: Relative number of fibres considered as open according to different
decision criteria of the percentage of fibre area free of clotting.
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before the planned dialysis end. Using a reference technique to
visualize individual fibres, this study indicates that fibre block-
ing can happen to a substantial degree without the need to stop
the dialysis session, and even without being noticed. This study
is, to our knowledge, the first to use the recently described
micro-CT scan technique [6] to compare different dialyser types
with regard to their capacity to induce clotting. It demonstrates
that this sensitive technique can provide useful and clinically
relevant information for the decision on which membrane type
to select.
Patients with ESKD have a substantially increased cardiovas-
cular risk as compared with age-matched persons without kid-
ney disease. Cumulative retention of products in the middle
molecular weight range 15–45 kDa substantially contributes to
this enhanced cardiovascular mortality by inducing inflamma-
tion. Removal of possibly pro-inflammatory uraemic retention
products is thus a potential strategy to reduce inflammation,
and hopefully, to improve patient outcomes. It is, however,
of importance to keep in mind that contact with the dialysis
membrane itself can induce inflammation due to bio-
incompatibility. Conventional high-flux dialysers do not effi-
ciently remove molecules in the middle molecular weight
range, such as b2M, tumour necrosis factor-a, interleukins,
kappa and lambda FLCs, or myoglobin, resulting in their
accumulation in patients with ESKD [1, 23–27]. HDF with post-
dilution, however, does effectively result in enhanced removal
of these middle molecules [28]. Our study indicates that the re-
duction ratios of kappa and lambda FLCs and of myoglobin were
not different from Solacea
TM
as compared with FX800CORDIAX
when used in post-dilution HDF with standard anticoagulation.
However, the myoglobin extraction ratio was found to decrease,
already at 60 min, in case of lower anticoagulation. The reduc-
tion ratios we have found for the FX800CORDIAX were com-
pared with those reported previously by others using the same
HDF parameters [25]. Using the Solacea
TM
in post-dilution HDF is
most likely still inferior for removal of lambda and kappa FLCs
than a medium cut off (MCO) membrane [25]. However, these
MCO membranes result in a substantial Alb loss of >3.5 g per
session with FX800CORDIAX. Alb loss with the SolaceaTM mem-
brane has been evaluated before and was reported to be
Table 5. Uraemic toxin and Alb concentrations in blood and dialysate in different experimental settings
Solacea_1/1 Solacea_1/2 FX800CORDIAX_1/1 FX800CORDIAX_1/2
Urea, mg/dL
Arterial 65.36 19.4 61.5625.7 63.56 23.7 60.26 26.3
Venous 6.06 2.2 8.167.2 5.76 1.7 5.96 2.0
Dialysate 29.26 11.1 29.5613.8 29.06 9.6 28.86 11.5
Alb (g/L)
Arterial 38.16 4.4 38.76 3.5 38.16 4.3 38.06 3.6
Venous 39.36 4.8 41.0611.2 39.06 4.8 39.46 4.8
Dialysate LOD LOD LOD LOD
Myoglobin (mg/L)
Arterial 1296 70 1036 45 1496 95 1186 66
Venous 91.56 54.8 69.8632.0 1136 69 94.96 51.1
Dialysate 26.96 3.8 26.66 2.3 28.56 7.7 26.06 4.3
Kappa FLC, mg/L
Arterial 79.46 40.1 84.2636.5 78.16 39.8 70.06 36.6
Venous 64.46 31.5 64.9629.4 61.66 34.2 55.56 34.1
Dialysate 2.66 1.7 2.861.5 2.46 1.9 2.66 2.0
Lambda FLC, mg/L
Arterial 1026 45 1106 45 90.06 56.8 90.56 43.2
Venous 69.66 26.9 71.2627.6 67.76 36.4 59.86 36.4
Dialysate 3.16 1.7 3.261.3 2.66 1.8 3.06 2.4
Values are expressed as mean6SD. LOD <4 g/L.
Table 6. Membrane adsorption and extraction ratios
P-value
Solacea_1/1 Solacea_1/2 FX800CORDIAX_1/1 FX800CORDIAX_1/2 ANOVA t-testa t-testb
Membrane adsorption (g/dialysis)
Kappa FLC 0.8960.64 1.1860.67 0.8460.99 0.8460.64 0.71 0.40 0.40
Lambda FLC 2.0761.36 2.5761.32 2.3861.20 1.9661.45 0.73 0.41 0.61
Extraction ratio (%)
Urea 9162 8768 9162 8964 0.31 0.47 0.10
Myoglobin 32610 34612 2468 2268* 0.02 0.01 0.97
Kappa FLC 2164 25613 2367 2566 0.63 0.52 0.28
Lambda FLC 3268 3768 3866 38612 0.46 0.37 0.27
aSolacea versus FX800CORDIAX.
bFull anticoagulation versus half-dose anticoagulation.
*P<0.05 versus Solacea_1/2.
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between 1 and 3 g for a regular dialysis session using very sensi-
tive analytical techniques [29, 30]. In our study, Alb loss in the
dialysate was below the detection limit of our routine detection
method for Alb in dialysate (0.9 mg/dL). As total dialysate vol-
ume spent during a regular dialysis session is around 200 L, this
confirms that Alb loss should not be considered as clinically rel-
evant problem when using these membranes in routine clinical
practice. There was also no evidence for Alb adherence to the
SolaceaTM membrane in our experiments.
Whereas the small patient number (n¼ 10) can be considered
as a limitation, this allowed us to use each patient as his own
control over the four experimental regimens. Also, patients
were dialysed only twice at the half dose of their regular antico-
agulation regime.
As a strength, we have used a very sensitive reference
method that allows us to measure coagulation in an objective
way. Even using this sensitive method, little or no sign of fibre
blocking was apparent when using the Solacea
TM
membrane.
In conclusion, the Solacea
TM
membrane seems to be ideal in
conditions where systemic anticoagulation is prohibited as it
outperforms polysulfone membranes under conditions of low
systemic anticoagulation. Further research to explore whether
this also reflects better biocompatibility, in general, are also
warranted.
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